Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience

作者：Schmohl Joerg U; Groh Christiane; Faul Christoph; Vogel Wichard; Moehle Robert; Wirths Stefan; Schneidawind Dominik; Kanz Lothar; Bethge Wolfgang A^*

来源：Annals of Hematology, 2016, 95(6): 973-983.

DOI：10.1007/s00277-016-2644-8

• Reduced intensity conditioning
• Myeloablative conditioning
• Hematopoietic cell transplantation
• Myelofibrosis

Myelofibrosis (MF) is a rare disease responsible for an increasing ineffective hematopoesis by a progressive fibrosing process in the bone marrow. The only curative treatment option is allogeneic hematopoietic cell transplantation (HCT). In this single-center analysis, we evaluated retrospectively 54 consecutive patients suffering from primary or secondary MF which underwent HCT from 1997 to 2014 after either myeloablative (MAC, n = 19) or reduced-intensity conditioning (RIC, n = 35). Overall survival (OS) and disease-free survival (DFS) after 3 years was 54/53 % for RIC versus 63/58 % for MAC (p = 0.8/0.97). Cumulative incidence of relapse was 34 % after RIC and 8 % after MAC (p = 0.16). Three-year non-relapse mortality (NRM) was 15 % after RIC and 34 % after MAC (p = 0.29). We found that RIC was associated with a lower incidence of acute graft versus host disease (GvHD; II-IV 26 vs. 0 %, p = 0.004). Evaluation of prognostic relevance of the Dynamic International Prognostic Scoring System (DIPSS) score showed a significant better OS in patient with risk score a parts per thousand currency sign3 versus > 3 (after 3 years, 71 vs. 39 %, p = 0.008). While similar OS and DFS were observed with MAC or RIC, the use of RIC resulted in lower incidence of acute GvHD. RIC regimens may be therefore the preferred conditioning approach for allogeneic HCT in patients with MF.

• 出版日期2016-5